



3 July 2015

**ASX RELEASE**

**Cleansing Notice – Share purchase plan**

Under ASIC Class Order 09/425 (**CO 09/425**), Anatara Lifesciences Limited (ASX: ANR) (**Anatara**) gives notice that:

- 1 Anatara will make offers to issue ordinary shares under a share purchase plan (**SPP**) without disclosure under part 6D.2 *Corporations Act 2001* (Cth) (**Corporations Act**);
- 2 this notice is given under CO 09/425 and in particular, paragraph 7(f)(ii) of CO 09/425 which requires that Anatara gives this notice to ASX within the 24 hour period before the SPP offer;
- 3 at the date of this notice, Anatara has complied with:
  - (a) the provisions of chapter 2M Corporations Act as they apply to Anatara; and
  - (b) section 674 Corporations Act; and
- 4 at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) Corporations Act, as if this notice were a notice under section 708A(5)(e) Corporations Act).

For and on behalf of the board of Anatara.

Mel Bridges  
Chairman  
Anatara Lifesciences Limited

For personal use only





ANATARA  
LIFESCIENCES

**For more information please contact:**

**General inquiries**

Mel Bridges

Chairman

+61 (0) 413 051 600

[melbridges@parmacorp.com](mailto:melbridges@parmacorp.com)

**Media inquiries**

Gavin Lower

Buchan Consulting

+61 3 8866 1215

[glower@buchanwe.com.au](mailto:glower@buchanwe.com.au)

**About Anatara Lifesciences**

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

For personal use only

